The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments trail-mediated apoptosis through c-FLIP down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation

Neoplasia

Volumn 12, Issue 4, 2010, Pages 346-356

  Fan, Songqing ^a,b   Li, Yikun ^a   Yue, Ping ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; INITIATION FACTOR 4G; SMALL INTERFERING RNA; SMALL MOLECULE 4EGI 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

EID: 77951671938     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10144     Document Type: Article

References (55)

1. von der Haar T, Gross JD, Wagner G, and McCarthy JE (2004). The mRNA cap-binding protein eIF4E in post-transcriptional gene expression. Nat Struct Mol Biol 11, 503-511.
2. Richter JD and Sonenberg N (2005). Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433, 477-480.
3. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, and Sonenberg N (2004). eIF4E-from translation to transformation. Oncogene 23, 3172-3179.
4. Graff JR, Konicek BW, Carter JH, and Marcusson EG (2008). Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68, 631-634.
5. De Benedetti A and Graff JR (2004). eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199.
6. Goodfellow IG and Roberts LO (2007). Eukaryotic initiation factor 4E. Int J Biochem Cell Biol 40, 2675-2680.
7. Raught B and Gingras AC (1999). eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31, 43-57.
8. Thumma SC and Kratzke RA (2007). Translational control: a target for cancer therapy. Cancer Lett 258, 1-8.
9. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, et al. (2004). Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5, 553-563.
10. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, and Lowe SW (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337.
11. Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, and Wendel HG (2008). Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22, 2178-2188.
12. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, and Pandolfi PP (2004). The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10, 484-486.
13. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, and Igarashi K (1997). Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57, 5041-5044.
14. Rousseau D, Gingras AC, Pause A, and Sonenberg N (1996). The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13, 2415-2420.
15. Li S, Sonenberg N, Gingras AC, Peterson M, Avdulov S, Polunovsky VA, and Bitterman PB (2002). Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 22, 2853-2861.
16. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al. (2007). Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117, 2638-2648.
17. Sawyers CL (2003). Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4,343-348.
18. Le Tourneau C, Faivre S, Serova M, and Raymond E (2008). mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99,1197-1203.
19. Abraham RT and Gibbons JJ (2007). The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13,3109-3114.
20. Kelley SK and Ashkenazi A (2004). Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4, 333-339.
21. Bellail AC, Qi L, Mulligan P, Chhabra V, and Hao C (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4, 34-41.
22. Rowinsky EK (2005). Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23, 9394-9407.
23. Ashkenazi A (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325-331.
24. Takeda K, Stagg J, Yagita H, Okumura K, and Smyth MJ (2007). Targeting death- inducing receptors in cancer therapy. Oncogene 26, 3745-3757.
25. Zhang L and Fang B (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12, 228-237.
26. Elrod HA and Sun SY (2007). Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 7, 163-173.
27. Krueger A, Baumann S, Krammer PH, and Kirchhoff S (2001). FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21, 8247-8254.
28. Budd RC, Yeh WC, and Tschopp J (2006). cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 6, 196-204.
29. Wajant H (2003). Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 3, 124-127.
30. Kataoka T (2005). The caspase-8 modulator c-FLIP. Crit Rev Immunol 25, 31-58.
31. Kim Y, Suh N, Sporn M, and Reed JC (2002). An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277, 22320-22329.
32. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, Johnson MS, Sistonen L, and Eriksson JE (2005). Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 280, 27345-27355.
33. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, and Karin M (2006). The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613.
34. Kamarajan P, Sun NK, and Chao CC (2003). Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem J 376,253-260.
35. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, and Johnston PG (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25, 838-848.
36. Abedini MR, Qiu Q, Yan X, and Tsang BK (2004). Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23,6997-7004.
37. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM, Johnston PG, and Longley DB (2007). c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67, 5754-5762.
38. Rogers KM, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, Johnston PG, and Longley DB (2007). Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 6, 1544-1551.
39. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al. (2007). Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257-267.
40. Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, Khuri FR, and Sun SY (2008). The natural product honokiol preferentially inhibits cellular FLICE- inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 7, 2212-2223.
41. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, et al. (1997). Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non- small cell lung carcinoma cells. Cancer Res 57, 4931-4939.
42. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, and Lotan R (1999). Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 18, 2357-2365.
43. Liu X, Yue P, Zhou Z, Khuri FR, and Sun SY (2004). Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 96,1769-1780.
44. Sun SY, Liu X, Zou W, Yue P, Marcus AI, and Khuri FR (2007). The farnesyl- transferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 282, 18800-18809.
45. Wang X and Proud CG (2007). Methods for studying signal-dependent regulation of translation factor activity. Methods Enzymol 431, 113-142.
46. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW, and Dong JT (2005). Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 24, 3319-3327.
47. Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, and Sonenberg N (2005). Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol 25, 10556-10565.
48. Lin YD, Chen S, Yue P, Zou W, Benbrook D, Liu S, Le TC, Berlin KD, Khuri FR, and Sun SY (2008). CAAT/enhancer binding protein homologous protein- dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res 68, 5335-5344.
49. Sabatini DM (2006). mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6, 729-734.
50. Yamaguchi H and Wang HG (2004). CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279, 45495-45502.
51. Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, and Sakai T (2005). Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 65, 6364-6370.
52. Panner A, James CD, Berger MS, and Pieper RO (2005). mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25,8809-8823.
53. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, and Fulda S (2008). Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68, 6271-6280.
54. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, and Sakai T (2005). Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65, 5662-5667.
55. Oyadomari S and Mori M (2004). Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11, 381-389.